Publications by authors named "Nan-Yao Wang"
World J Clin Cases
March 2024
Article Synopsis
- Pancreatic cancer has a very low five-year survival rate of less than 10%, and treatment options become even more limited in later stages; however, anti-angiogenic drugs like fruquintinib show promise in improving outcomes by targeting tumor blood vessel growth and the immune environment.
- This summary discusses two cases where patients with advanced pancreatic cancer experienced prolonged progression-free survival (PFS) of 10 months each while using fruquintinib as a third-line treatment after multiple previous therapies.
- The findings suggest that fruquintinib could be a viable option for patients with limited treatment choices, warranting further investigation to assess its potential benefits and safety in managing pancreatic cancer.
